BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).

Alterity Therapeutics today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), were published in The New England Journal of Medicine (NEJM).

HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff , PhD, as interim chief executive officer.

Stoke Therapeutics today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

BiondVax Pharmaceuticals Ltd. today published its financial results for the quarter ended June 30, 2022 and provided a business update.

Aptinyx Inc. today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMice TM platform.

Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc., announced its ATOM® Phantom product line will play a vital role in the first of a series of NASA missions aimed at enabling human exploration to the Moon and Mars.